Wegovy contains the active ingredient semaglutide, a GLP-1 agonist
Vasanthakumar S, Sasikala P, Padma M, Balachandar V, Venkatesh B, Ganesan S
Routes of Administration: Injection and Oral Capsules BPC-157 can be administered in two primary forms, each with its own advantages depending on the intended use: Subcutaneous Injection: Direct and Targeted: Injections allow for direct delivery into the bloodstream, making it the preferred route for systemic effects or for targeting specific injuries
Each vial contains sterile water with 0.9% benzyl alcohol to help inhibit microbial growth during repeated laboratory handling under appropriate sterile conditions
Comparison with Similar Peptides GHK-Cu (Current) Half-Life:~2 hours Dosage:1-2 mg daily Administration:Topical or subcutaneous Research Status: Preclinical/Experimental Half-Life:~4 hours Dosage:200-500 mcg daily Administration:Subcutaneous injection Research Status: Preclinical/Experimental Half-Life:~2-3 days Dosage:2-5 mg per week Administration:Subcutaneous injection Research Status: Preclinical/Experimental Half-Life:~2-3 hours Dosage:2-4 IU daily Administration:Subcutaneous injection Research Status: FDA Approved (for specific conditions) Half-Life:~24 hours Dosage:10-25 mg daily Administration:Oral Research Status: Experimental Half-Life:~12 minutes Dosage:1-2 mg daily Administration:Subcutaneous injection Research Status: FDA Approved (for specific conditions) Highlighted rowcard shows the current peptide
View Our Interactive Dashboard on GLP-1RA Therapies in Development (Free Excel Available) Our view With the rise in urbanization, affluence and sedentary lifestyles, the incidence of diabetes, heart and liver diseases and obesity is increasing
